CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals mixed signals. The financial performance shows a significant decrease in revenue, but there's a substantial increase in cash reserves due to recent financing. Product development and market strategy show promise with Varseta-M's ongoing studies and future plans, but there's uncertainty in execution and FDA interactions. The Q&A section highlights management's lack of clarity on some issues, which could concern investors. The overall sentiment is neutral, as positive long-term prospects are balanced by short-term uncertainties and financial challenges.
Key Financial Performance
Cash, Cash Equivalents, and Investments $346.7 million as of March 31, 2026, compared to $137.1 million as of December 31, 2025. This increase is attributed to financing completed in March 2026.
Total Revenue $10.3 million for Q1 2026, compared to $50.9 million for Q1 2025. The decrease is primarily due to the completion of obligations in 2025 under collaborations with Bristol Myers Squibb and Amgen.
Operating Expenses $29.8 million for Q1 2026, compared to $28.3 million for Q1 2025. The increase is attributed to higher R&D and G&A expenses.
R&D Expenses $19.2 million for Q1 2026, an increase of $0.4 million compared to Q1 2025. This increase is primarily due to increased manufacturing activities for Varseta-M, partially offset by $1.8 million in restructuring expenses incurred in Q1 2025.
G&A Expenses $10.6 million for Q1 2026, compared to $9.4 million for Q1 2025. The increase of $1.1 million is attributed to one-time restructuring expenses in Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Varseta-M: Varseta-M is a first-in-class EpCAM targeting antibody drug conjugate (ADC) designed using CytomX's proprietary PROBODY therapeutic masking platform. It is being developed for late-line colorectal cancer (CRC) and has shown promising Phase I data with a confirmed overall response rate between 20%-32% and approximately 7 months of median progression-free survival. The drug is also being explored for other cancers and as a pan-tumor therapy.
CX-801: CX-801 is a masked interferon alpha-2b program in Phase I development for advanced checkpoint refractory melanoma. It aims to become a centerpiece for combination cancer immunotherapy. Early data suggest it is well-tolerated and effective, with combination dose escalation with KEYTRUDA progressing well.
Colorectal Cancer Market: Varseta-M targets metastatic CRC, a multibillion-dollar market with significant unmet needs. The drug aims to become a core component of the standard of care and potentially replace systemic irinotecan and chemotherapy in CRC treatment.
Pan-Tumor Potential: Varseta-M is being developed for additional EpCAM-expressing cancers beyond CRC, with Phase I expansion cohorts planned for the second half of 2026.
Clinical Progress: Varseta-M has completed enrollment in dose optimization cohorts with 40 patients, totaling 113 patients in the Phase I study. The company is on track for a Phase I data update in the second half of 2026 and plans to initiate a registrational study in 2027.
Financial Position: CytomX has $346.7 million in cash as of March 31, 2026, providing a runway until at least the second half of 2028. The company is focused on advancing Varseta-M and achieving multiple milestones.
Strategic Combinations: Varseta-M is being tested in combination with bevacizumab and chemotherapy to enable earlier line utilization in CRC. Initial data for these combinations are expected by 2027.
Focus on High-Impact Programs: CytomX is prioritizing Varseta-M and CX-801 development, allocating resources to maximize their potential in addressing unmet needs in oncology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Challenges: The company is focused on advancing Varseta-M to regulatory approval, which involves inherent risks such as meeting stringent regulatory requirements and potential delays in approval timelines.
Adverse Events Management: High-grade diarrhea has been identified as a principal adverse event for Varseta-M, requiring effective patient management strategies to mitigate risks and ensure patient safety.
Clinical Trial Risks: The ongoing dose optimization and registrational studies for Varseta-M involve uncertainties, including achieving the desired risk-benefit profile and potential challenges in patient enrollment or data outcomes.
Market Competition: Although Varseta-M is positioned as a first-in-class EpCAM targeting ADC, competitive pressures from other emerging therapies in colorectal cancer and other cancers could impact its market potential.
Financial Dependency on Varseta-M: The company’s capital allocation is highly focused on Varseta-M, making its financial health heavily reliant on the success of this single asset.
Revenue Decline: A significant decrease in revenue was reported due to the completion of obligations under collaborations with Bristol Myers Squibb and Amgen, which could impact short-term financial stability.
Economic and Operational Risks: Increased R&D and G&A expenses, along with dependency on existing cash reserves, pose risks to operational sustainability if milestones are not achieved as planned.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Varseta-M Development Timeline: CytomX plans to advance Varseta-M into a registrational study in late-line colorectal cancer (CRC) in the first half of 2027. Dose optimization is ongoing, with an update expected before the end of 2026. Initial clinical data for Varseta-M in combination with bevacizumab is expected by the first half of 2027. A Phase I/II chemotherapy combination study is planned for the second half of 2026.
Varseta-M Market Potential: Varseta-M is positioned as a transformative therapy for metastatic CRC, targeting a multibillion-dollar market in the late-line setting. The drug is also being developed for earlier-line CRC therapy and other EpCAM-expressing cancers, with the goal of becoming a pan-tumor therapy.
CX-801 Development Timeline: Initial clinical data for CX-801, a masked interferon alpha-2b program, is expected by the end of 2026. The program is currently in Phase I development for advanced checkpoint refractory melanoma, with combination dose escalation with KEYTRUDA actively enrolling.
Financial Guidance: CytomX has a cash runway projected to last until at least the second half of 2028. This financial position supports the advancement of Varseta-M into registrational studies, combination therapy trials, and exploration of additional indications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the scope of the clinical update for Varseta-M in the second half?
A:The update will be substantial, covering the entire study, including data from the 40-patient optimization phase. It will include safety and efficacy follow-up, an initial estimate of PFS, and a first look at OS. Subgroup demographics will also be communicated, emphasizing that Varseta-M is a drug for all-comer late-line CRC.
Q:Will the 1-2 chemo combo trial include Avastin, and is Avastin combo data required to start the trial?
A:Yes, the trial will evaluate Varseta-M plus chemo plus bevacizumab (Avastin). However, data from the ongoing Varseta-M plus bevacizumab combination is not gating for starting the chemo combo trial in the second half.
Q:What is the prioritization strategy for new EpCAM-positive tumors?
A:EpCAM is broadly expressed in many solid tumors, and prioritization is ongoing. Adjacent GI tumors are a logical focus, but more specifics will be communicated in the second half.
Q:How does the dose optimization update relate to FDA interactions and pivotal trial design?
A:The dose optimization data will be central to FDA discussions, particularly for dose selection in the first pivotal study. The next comprehensive update by year-end will include data from the 113-patient Phase I study and guidance on pivotal study design, patient population, comparator arm, and dose.
Q:What is the decision-making framework for selecting between the 8.6 mg/kg and 10 mg/kg doses?
A:The decision will be based on efficacy (ORR, PFS, OS) and safety data from the dose optimization cohorts. Both doses show remarkable activity, with ORR of 20% at 8.6 mg/kg and 32% at 10 mg/kg. OS is expected to be the primary endpoint for the pivotal study.
Q:Will the second-half data disclosure include tolerability and efficacy for the 40-patient optimization cohort?
A:Yes, the disclosure will include the full safety picture and efficacy data, including PFS for the 40 patients. OS data for these patients is expected to be immature, but OS data from earlier phases will be included.
Q:What adjustments are being made to Varseta-M's dosing schedule for combination with bevacizumab?
A:The dosing schedule is being adjusted from every 3 weeks to every 2 or 4 weeks to match the established clinical use of bevacizumab in the FOLFOX/FOLFIRI setting. No formulation changes are required.
Q:How does Varseta-M compare to other ADCs in development, and is this a winner-takes-all scenario?
A:Varseta-M is a first-in-class anti-EpCAM ADC with potential to be best-in-class for colorectal cancer. It shows high activity in ORR and PFS and is expected to deliver strong OS results. The market is not seen as winner-takes-all, and Varseta-M is positioned as highly competitive.
Q:What is the current status of Grade 3 or higher diarrhea rates in the dose optimization cohort?
A:No new data was provided, but initial data showed a 10% rate of Grade 3 diarrhea with the updated AE management strategy. The goal is to manage rates to 10%-20%, with more data expected later in the year.
Q:Is the prophylaxis strategy for Varseta-M optimized for community oncology settings?
A:Yes, the current optimization work aims to establish a prophylaxis strategy that can be readily translated into community settings and the commercial marketplace.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the prioritization of new EpCAM-positive tumors, stating only that prioritization is ongoing and more specifics will be communicated later. Additionally, they did not provide updated data on Grade 3 diarrhea rates, deferring this information to a later update.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
CRC opportunity
CX
CytomX start
PROBODY
Phase development
Sean
afternoon
alphab
cancer
cash
cohort patient
combination bevacizumab
combination chemotherapy
creation potential
cytokine
drug
efficacy
escalation
indication
line CRC
monotherapy dose
need melanoma
optimization cohort
position
potential CytomX
response rate
safety
study dose
study line
treatment
tumor
urgency
week
CTMX Transcript
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary reveals mixed signals. The financial performance shows a significant decrease in revenue, but there's a substantial increase in cash reserves due to recent financing. Product development and market strategy show promise with Varseta-M's ongoing studies and future plans, but there's uncertainty in execution and FDA interactions. The Q&A section highlights management's lack of clarity on some issues, which could concern investors. The overall sentiment is neutral, as positive long-term prospects are balanced by short-term uncertainties and financial challenges.
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
Unknown3-16
The earnings call summary indicates a mixed sentiment. The financial guidance and new developments show promise, but lack specifics and clarity, especially in the Q&A section, where management avoided providing detailed responses. The absence of a market cap makes it difficult to assess the stock's potential movement accurately. However, the company's ongoing efforts in product development and strategic plans for various tumor types provide a balanced outlook, resulting in a neutral sentiment.
CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call reveals a significant decline in total revenue, primarily due to the completion of obligations in a major collaboration. While operating expenses decreased, the revenue drop is concerning. The Q&A section highlights some optimism about CX-2051's potential, but uncertainties remain, particularly regarding regulatory strategies and data updates. No guidance was provided, and management's evasiveness on certain questions adds to the negative sentiment. Overall, the financial performance and lack of clear guidance suggest a negative outlook for the stock price in the short term.
CTMX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
